
## K Michael Gibson

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9319312/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Farnesol induces protection against murine CNS inflammatory demyelination and modifies gut microbiome. Clinical Immunology, 2022, 235, 108766.	3.2	13
2	Intestinal Dysbiosis as a component of pathophysiology in succinic semialdehyde dehydrogenase deficiency (SSADHD). Molecular Genetics and Metabolism, 2022, 135, 42-46.	1.1	2
3	Discovery and Optimization of 5-Hydroxy-Diclofenac toward a New Class of Ligands with Nanomolar Affinity for the CaMKIIα Hub Domain. Journal of Medicinal Chemistry, 2022, 65, 6656-6676.	6.4	3
4	Dysbiosis of the intestinal microbiome as a component of pathophysiology in the inborn errors of metabolism. Molecular Genetics and Metabolism, 2021, 132, 1-10.	1.1	11
5	Succinic Semialdehyde Dehydrogenase Deficiency: Review of the Natural History Study. Journal of Child Neurology, 2021, 36, 1153-1161.	1.4	15
6	Postmortem Analyses in a Patient With Succinic Semialdehyde Dehydrogenase Deficiency (SSADHD): II. Histological, Lipid, and Gene Expression Outcomes in Regional Brain Tissue. Journal of Child Neurology, 2021, 36, 1177-1188.	1.4	7
7	Preferential accumulation of the active S-(+) isomer in murine retina highlights novel mechanisms of vigabatrin-associated retinal toxicity. Epilepsy Research, 2021, 170, 106536.	1.6	3
8	A Randomized Controlled Trial of SGS-742, a Î <sup>3</sup> -aminobutyric acid B (GABA-B) Receptor Antagonist, for Succinic Semialdehyde Dehydrogenase Deficiency. Journal of Child Neurology, 2021, 36, 1189-1199.	1.4	6
9	Author Response: Novel ALDH5A1 Variants and Genotype: Phenotype Correlation in SSADH Deficiency. Neurology, 2021, 96, 1060-1060.	1.1	0
10	Development of a Quality-of-Life Survey for Patients With Succinic Semialdehyde Dehydrogenase Deficiency, a Rare Disorder of GABA Metabolism. Journal of Child Neurology, 2021, 36, 1223-1230.	1.4	2
11	Novel Dual-Organelle-Targeting Probe (RCPP) for Simultaneous Measurement of Organellar Acidity and Alkalinity in Living Cells. ACS Omega, 2021, 6, 31447-31456.	3.5	9
12	Transcriptome analysis in mice treated with vigabatrin identifies dysregulation of genes associated with retinal signaling circuitry. Epilepsy Research, 2020, 166, 106395.	1.6	2
13	Novel <i>ALDH5A1</i> variants and genotype. Neurology, 2020, 95, e2675-e2682.	1.1	14
14	Novel biomarkers and age-related metabolite correlations in plasma and dried blood spots from patients with succinic semialdehyde dehydrogenase deficiency. Orphanet Journal of Rare Diseases, 2020, 15, 261.	2.7	3
15	Cellular and molecular outcomes of glutamine supplementation in the brain of succinic semialdehyde dehydrogenase <scp>â€deficient</scp> mice. JIMD Reports, 2020, 56, 58-69.	1.5	3
16	A Missense Variant in ALDH5A1 Associated with Canine Succinic Semialdehyde Dehydrogenase Deficiency (SSADHD) in the Saluki Dog. Genes, 2020, 11, 1033.	2.4	3
17	Functional analysis of thirty-four suspected pathogenic missense variants in ALDH5A1 gene associated with succinic semialdehyde dehydrogenase deficiency. Molecular Genetics and Metabolism, 2020, 130, 172-178.	1.1	8
18	Longitudinal metabolomics in dried bloodspots yields profiles informing newborn screening for succinic semialdehyde dehydrogenase deficiency. JIMD Reports, 2020, 53, 29-38.	1.5	3

#	Article	IF	CITATIONS
19	Post-mortem tissue analyses in a patient with succinic semialdehyde dehydrogenase deficiency (SSADHD). I. Metabolomic outcomes. Metabolic Brain Disease, 2020, 35, 601-614.	2.9	16
20	Vigabatrin-Induced Retinal Functional Alterations and Second-Order Neuron Plasticity in C57BL/6J Mice. , 2020, 61, 17.		11
21	Zellweger spectrum disorder: A cross-sectional study of symptom prevalence using input from family caregivers. Molecular Genetics and Metabolism Reports, 2020, 25, 100694.	1.1	4
22	Microbiota Manipulation as a Metagenomic Therapeutic Approach for Rare Inherited Metabolic Disorders. Clinical Pharmacology and Therapeutics, 2019, 106, 505-507.	4.7	5
23	Gamma-Hydroxybutyrate content in dried bloodspots facilitates newborn detection of succinic semialdehyde dehydrogenase deficiency. Molecular Genetics and Metabolism, 2019, 128, 109-112.	1.1	10
24	Temporal metabolomics in dried bloodspots suggests multipathway disruptions in aldh5a1 mice, a model of succinic semialdehyde dehydrogenase deficiency. Molecular Genetics and Metabolism, 2019, 128, 397-408.	1.1	6
25	Cardioprotection Effects of <b>LPTC-5</b> Involve Mitochondrial Protection and Dynamics. ACS Omega, 2019, 4, 9868-9877.	3.5	1
26	Maternal glutamine supplementation in murine succinic semialdehyde dehydrogenase deficiency, a disorder of γâ€aminobutyric acid metabolism. Journal of Inherited Metabolic Disease, 2019, 42, 1030-1039.	3.6	4
27	Dâ€⊋â€hydroxyglutaric aciduria Type I: Functional analysis of <i>D2HGDH</i> missense variants. Human Mutation, 2019, 40, 975-982.	2.5	8
28	Rett syndrome ( MECP2 ) and succinic semialdehyde dehydrogenase ( ALDH5A1 ) deficiency in a developmentally delayed female. Molecular Genetics & Genomic Medicine, 2019, 7, e629.	1.2	2
29	Emotional experience in parents of children with Zellweger spectrum disorders: A qualitative study. Molecular Genetics and Metabolism Reports, 2019, 19, 100459.	1.1	14
30	Ageâ€related phenotype and biomarker changes in <scp>SSADH</scp> deficiency. Annals of Clinical and Translational Neurology, 2019, 6, 114-120.	3.7	27
31	Preclinical tissue distribution and metabolic correlations of vigabatrin, an antiepileptic drug associated with potential useâ€limiting visual field defects. Pharmacology Research and Perspectives, 2019, 7, e00456.	2.4	10
32	Metabolomic analyses of vigabatrin (VGB)-treated mice: GABA-transaminase inhibition significantly alters amino acid profiles in murine neural and non-neural tissues. Neurochemistry International, 2019, 125, 151-162.	3.8	13
33	Membraneâ€Facilitated Allosteric Modulation of GABA A Receptor by Farnesol: An In Silico Modeling and Simulation Study. FASEB Journal, 2019, 33, 809.8.	0.5	0
34	Succinic semialdehyde dehydrogenase deficiency, a disorder of GABA metabolism: an update on pharmacological and enzymeâ€replacement therapeutic strategies. Journal of Inherited Metabolic Disease, 2018, 41, 699-708.	3.6	30
35	Toxicologic/transport properties of NCS-382, a Î <sup>3</sup> -hydroxybutyrate (GHB) receptor ligand, in neuronal and epithelial cells: Therapeutic implications for SSADH deficiency, a GABA metabolic disorder. Toxicology in Vitro, 2018, 46, 203-212.	2.4	10
36	Indole Alkaloid Derivative B, a Novel Bifunctional Agent That Mitigates 5-Fluorouracil-Induced Cardiotoxicity. ACS Omega, 2018, 3, 15850-15864.	3.5	10

#	Article	IF	CITATIONS
37	In vitro toxicological evaluation of NCS-382, a high-affinity antagonist of Î <sup>3</sup> -hydroxybutyrate (GHB) binding. Toxicology in Vitro, 2017, 40, 196-202.	2.4	5
38	Phenotype of GABA-transaminase deficiency. Neurology, 2017, 88, 1919-1924.	1.1	49
39	Oral D-galactose supplementation in PGM1-CDG. Genetics in Medicine, 2017, 19, 1226-1235.	2.4	55
40	Gamma-Hydroxybutyrate (GHB) Content in Hair Samples Correlates Negatively with Age in Succinic Semialdehyde Dehydrogenase Deficiency. JIMD Reports, 2017, 36, 93-98.	1.5	9
41	Targeted screening of succinic semialdehyde dehydrogenase deficiency (SSADHD) employing an enzymatic assay for γ-hydroxybutyric acid (GHB) in biofluids. Molecular Genetics and Metabolism Reports, 2017, 11, 81-89.	1.1	4
42	Indole-TEMPO conjugates alleviate ischemia-reperfusion injury via attenuation of oxidative stress and preservation of mitochondrial function. Bioorganic and Medicinal Chemistry, 2017, 25, 2545-2568.	3.0	11
43	Therapeutic relevance of mTOR inhibition in murine succinate semialdehyde dehydrogenase deficiency (SSADHD), a disorder of GABA metabolism. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2017, 1863, 33-42.	3.8	10
44	Aberrant mTOR signaling and disrupted autophagy: The missing link in potential vigabatrinâ€associated ocular toxicity?. Clinical Pharmacology and Therapeutics, 2017, 101, 458-461.	4.7	6
45	Multicompartment analysis of proteinâ€restricted phenylketonuric mice reveals amino acid imbalances in brain. Journal of Inherited Metabolic Disease, 2017, 40, 227-235.	3.6	10
46	mTOR Inhibition Mitigates Molecular and Biochemical Alterations of Vigabatrin-Induced Visual Field Toxicity in Mice. Pediatric Neurology, 2017, 66, 44-52.e1.	2.1	16
47	In vitro modeling of experimental succinic semialdehyde dehydrogenase deficiency (SSADHD) using brain-derived neural stem cells. PLoS ONE, 2017, 12, e0186919.	2.5	5
48	mTOR, Autophagy, Aminoacidopathies, and Human Genetic Disorders. , 2016, , 143-166.		1
49	A pharmacokinetic evaluation and metabolite identification of the <scp>GHB</scp> receptor antagonist <scp>NCS</scp> â€382 in mouse informs novel therapeutic strategies for the treatment of <scp>GHB</scp> intoxication. Pharmacology Research and Perspectives, 2016, 4, e00265.	2.4	11
50	Correlation of blood biomarkers with age informs pathomechanisms in succinic semialdehyde dehydrogenase deficiency (SSADHD), a disorder of GABA metabolism. Journal of Inherited Metabolic Disease, 2016, 39, 795-800.	3.6	20
51	Pharmacological protection of mitochondrial function mitigates acute limb ischemia/reperfusion injury. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 4042-4051.	2.2	12
52	Succinic semialdehyde dehydrogenase deficiency (SSADHD): Pathophysiological complexity and multifactorial trait associations in a rare monogenic disorder of GABA metabolism. Neurochemistry International, 2016, 99, 72-84.	3.8	60
53	mTOR inhibitors rescue premature lethality and attenuate dysregulation of GABAergic/glutamatergic transcription in murine succinate semialdehyde dehydrogenase deficiency (SSADHD), a disorder of GABA metabolism. Journal of Inherited Metabolic Disease, 2016, 39, 877-886.	3.6	23
54	Incidence and Geographic Distribution of Succinic Semialdehyde Dehydrogenase (SSADH) Deficiency. JIMD Reports, 2016, 34, 111-115.	1.5	22

#	Article	IF	CITATIONS
55	Anti-inflammatory, analgesic and antioxidant activities of novel kyotorphin-nitroxide hybrid molecules. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 2005-2013.	2.2	12
56	Disorders of Neurotransmission. , 2016, , 415-427.		0
57	Disorders of GABA metabolism: SSADH and GABA-transaminase deficiencies. Journal of Pediatric Epilepsy, 2015, 03, 217-227.	0.2	63
58	Torin 1 partially corrects vigabatrinâ€induced mitochondrial increase in mouse. Annals of Clinical and Translational Neurology, 2015, 2, 699-706.	3.7	23
59	Biomarkers in a Taurine Trial for Succinic Semialdehyde Dehydrogenase Deficiency. JIMD Reports, 2015, 30, 81-87.	1.5	17
60	Inherited disorders of gammaâ€aminobutyric acid metabolism and advances in <i><scp>ALDH</scp>5A1</i> mutation identification. Developmental Medicine and Child Neurology, 2015, 57, 611-617.	2.1	44
61	Highly Stable and Sensitive Fluorescent Probes (LysoProbes) for Lysosomal Labeling and Tracking. Scientific Reports, 2015, 5, 8576.	3.3	66
62	Clinical Use of CSF Neurotransmitters. Pediatric Neurology, 2015, 53, 277-286.	2.1	164
63	Lysosomal Targeting with Stable and Sensitive Fluorescent Probes (Superior LysoProbes): Applications for Lysosome Labeling and Tracking during Apoptosis. Scientific Reports, 2015, 5, 9004.	3.3	68
64	Targeted fluorescent probes for detection of oxidative stress in the mitochondria. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 3476-3480.	2.2	13
65	Natural history of succinic semialdehyde dehydrogenase deficiency through adulthood. Neurology, 2015, 85, 861-865.	1.1	44
66	Physiological competition of brain phenylalanine accretion: Initial pharmacokinetic analyses of aminoisobutyric and methylaminoisobutyric acids in Pahenu2â^'/â^' mice. Molecular Genetics and Metabolism Reports, 2015, 3, 80-87.	1.1	2
67	Taurine trial in succinic semialdehyde dehydrogenase deficiency and elevated CNS GABA. Neurology, 2014, 82, 940-944.	1.1	30
68	Defects in <scp>GABA</scp> metabolism affect selective autophagy pathways and are alleviated by m <scp>TOR</scp> inhibition. EMBO Molecular Medicine, 2014, 6, 551-566.	6.9	67
69	Pharmacologic inhibition of Lâ€ŧyrosine degradation ameliorates cerebral dopamine deficiency in murine phenylketonuria (PKU). Journal of Inherited Metabolic Disease, 2014, 37, 735-743.	3.6	38
70	Therapeutic hepatocyte transplant for inherited metabolic disorders: functional considerations, recent outcomes and future prospects. Journal of Inherited Metabolic Disease, 2014, 37, 165-176.	3.6	8
71	Brain–blood amino acid correlates following protein restriction in murine maple syrup urine disease. Orphanet Journal of Rare Diseases, 2014, 9, 73.	2.7	17
72	Response to Stove and colleagues concerning newborn screening of succinic semialdehyde dehydrogenase (SSADH) deficiency in dried blood spots. Molecular Genetics and Metabolism, 2013, 110, 196.	1.1	1

#	Article	IF	CITATIONS
73	Nonâ€physiological amino acid (NPAA) therapy targeting brain phenylalanine reduction: pilot studies in <i>PAH</i> <sup><b><i>ENU2</i></b></sup> mice. Journal of Inherited Metabolic Disease, 2013, 36, 513-523.	3.6	17
74	Characterization of 2-(methylamino)alkanoic acid capacity to restrict blood–brain phenylalanine transport in Pahenu2 mice: Preliminary findings. Molecular Genetics and Metabolism, 2013, 110, S71-S78.	1.1	10
75	Improved Amino Acid, Bioenergetic Metabolite and Neurotransmitter Profiles following Human Amnion Epithelial Cell Transplant in Intermediate Maple Syrup Urine Disease Mice. Molecular Genetics and Metabolism, 2013, 109, 132-138.	1.1	42
76	Quantitation of gamma-hydroxybutyric acid in dried blood spots: Feasibility assessment for newborn screening of succinic semialdehyde dehydrogenase (SSADH) deficiency. Molecular Genetics and Metabolism, 2013, 109, 255-259.	1.1	29
77	Thirty years beyond discovery—Clinical trials in succinic semialdehyde dehydrogenase deficiency, a disorder of GABA metabolism. Journal of Inherited Metabolic Disease, 2013, 36, 401-410.	3.6	53
78	Placental stem cell correction of murine intermediate maple syrup urine disease. Hepatology, 2013, 57, 1017-1023.	7.3	58
79	Evidence for treatable inborn errors of metabolism in a cohort of 187 Greek patients with autism spectrum disorder (ASD). Frontiers in Human Neuroscience, 2013, 7, 858.	2.0	53
80	Therapeutic Efficacy of Magnesium Valproate in Succinic Semialdehyde Dehydrogenase Deficiency. JIMD Reports, 2012, 8, 133-137.	1.5	15
81	New Rhodamine Nitroxide Based Fluorescent Probes for Intracellular Hydroxyl Radical Identification in Living Cells. Organic Letters, 2012, 14, 50-53.	4.6	96
82	Succinic Semialdehyde Dehydrogenase: Biochemical–Molecular–Clinical Disease Mechanisms, Redox Regulation, and Functional Significance. Antioxidants and Redox Signaling, 2011, 15, 691-718.	5.4	68
83	Epilepsy in succinic semialdehyde dehydrogenase deficiency, a disorder of GABA metabolism. Brain and Development, 2011, 33, 796-805.	1.1	56
84	Familial 6p22.2 duplication associates with mild developmental delay and increased SSADH activity. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2011, 156, 448-453.	1.7	5
85	A new class of β-carboline alkaloid-peptide conjugates with therapeutic efficacy in acute limb ischemia/reperfusion injury. European Journal of Medicinal Chemistry, 2011, 46, 1453-1462.	5.5	20
86	Efficacy of Vigabatrin Intervention in a Mild Phenotypic Expression of Succinic Semialdehyde Dehydrogenase Deficiency. JIMD Reports, 2011, 2, 119-123.	1.5	13
87	A new case of GABA transaminase deficiency facilitated by proton MR spectroscopy. Journal of Inherited Metabolic Disease, 2010, 33, 85-90.	3.6	57
88	Neuropathology in Succinic Semialdehyde Dehydrogenase Deficiency. Pediatric Neurology, 2010, 42, 255-258.	2.1	27
89	Synthesis and Characterization of Novel Indole Derivatives Reveal Improved Therapeutic Agents for Treatment of Ischemia/Reperfusion (I/R) Injury. Journal of Medicinal Chemistry, 2010, 53, 6763-6767.	6.4	27
90	Plasticity of postsynaptic, but not presynaptic, GABAB receptors inSSADH deficient mice. Experimental Neurology, 2010, 225, 114-122.	4.1	16

#	Article	IF	CITATIONS
91	Cerebellar Atrophy in Human and Murine Succinic Semialdehyde Dehydrogenase Deficiency. Journal of Child Neurology, 2010, 25, 1457-1461.	1.4	11
92	Hepatocyte Transplantation Improves Phenotype and Extends Survival in a Murine Model of Intermediate Maple Syrup Urine Disease. Molecular Therapy, 2009, 17, 1266-1273.	8.2	30
93	Decreased GABA-A binding on FMZ-PET in succinic semialdehyde dehydrogenase deficiency. Neurology, 2009, 73, 423-429.	1.1	88
94	Succinic semialdehyde dehydrogenase deficiency: Lessons from mice and men. Journal of Inherited Metabolic Disease, 2009, 32, 343-352.	3.6	97
95	Hepatocyte transplantation (HTx) corrects selected neurometabolic abnormalities in murine intermediate maple syrup urine disease (iMSUD). Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2009, 1792, 1004-1010.	3.8	25
96	The effects of a ketogenic diet on ATP concentrations and the number of hippocampal mitochondria in Aldh5a1â^'/â^' mice. Biochimica Et Biophysica Acta - General Subjects, 2009, 1790, 208-212.	2.4	56
97	Comparative genomics of aldehyde dehydrogenase 5a1 (succinate semialdehyde dehydrogenase) and accumulation of gamma-hydroxybutyrate associated with its deficiency. Human Genomics, 2009, 3, 106.	2.9	30
98	SSADH deficiency leads to elevated extracellular GABA levels and increased GABAergic neurotransmission in the mouse cerebral cortex. Journal of Inherited Metabolic Disease, 2008, 31, 662-668.	3.6	18
99	Neurotransmitter alterations in embryonic succinate semialdehyde dehydrogenase (SSADH) deficiency suggest a heightened excitatory state during development. BMC Developmental Biology, 2008, 8, 112.	2.1	37
100	Circadian distribution of generalized tonic–clonic seizures associated with murine succinic semialdehyde dehydrogenase deficiency, a disorder of GABA metabolism. Epilepsy and Behavior, 2008, 13, 290-294.	1.7	18
101	A ketogenic diet rescues the murine succinic semialdehyde dehydrogenase deficient phenotype. Experimental Neurology, 2008, 210, 449-457.	4.1	54
102	Neuropsychiatric Morbidity in Adolescent and Adult Succinic Semialdehyde Dehydrogenase Deficiency Patients. CNS Spectrums, 2008, 13, 598-605.	1.2	54
103	Lipid abnormalities in succinate semialdehyde dehydrogenase (Aldh5a1â~'/â^') deficient mouse brain provide additional evidence for myelin alterations. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2007, 1772, 556-562.	3.8	18
104	Enzymatic and metabolic evidence for a region specific mitochondrial dysfunction in brains of murine succinic semialdehyde dehydrogenase deficiency (Aldh5a1â^'/â^' mice). Neurochemistry International, 2007, 50, 653-659.	3.8	39
105	Diagnostic challenges in a severely delayed infant with hypersomnolence, failure to thrive and arteriopathy: A unique case of γâ€hydroxybutyric aciduria and Williams syndrome. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2007, 144B, 946-948.	1.7	4
106	Altered cerebral glucose and acetate metabolism in succinic semialdehyde dehydrogenaseâ€deficient mice: evidence for glial dysfunction and reduced glutamate/glutamine cycling. Journal of Neurochemistry, 2007, 103, 2077-2091.	3.9	52
107	Therapeutic concepts in succinate semialdehyde dehydrogenase (SSADH; ALDH5a1) deficiency (γ-hydroxybutyric aciduria). Hypotheses evolved from 25Åyears of patient evaluation, studies in Aldh5a1 â^'/â´' mice and characterization of γ-hydroxybutyric acid pharmacology. Journal of Inherited Metabolic Disease. 2007. 30. 279-294.	3.6	39
108	Evidence for oxidative stress in tissues derived from succinate semialdehyde dehydrogenaseâ€deficient mice. Journal of Inherited Metabolic Disease, 2007, 30, 800-810.	3.6	31

#	Article	IF	CITATIONS
109	Metabolism of γ-hydroxybutyrate to d-2-hydroxyglutarate in mammals: further evidence for d-2-hydroxyglutarate transhydrogenase. Metabolism: Clinical and Experimental, 2006, 55, 353-358.	3.4	43
110	Increased guanidino species in murine and human succinate semialdehyde dehydrogenase (SSADH) deficiency. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2006, 1762, 494-498.	3.8	31
111	Succinate semialdehyde dehydrogenase deficiency does not down-regulate Î <sup>3</sup> -hydroxybutyric acid binding sites in the mouse brain. Molecular Genetics and Metabolism, 2006, 88, 86-89.	1.1	17
112	d-2-Hydroxyglutaric aciduria in three patients with proven SSADH deficiency: Genetic coincidence or a related biochemical epiphenomenon?. Molecular Genetics and Metabolism, 2006, 88, 53-57.	1.1	13
113	A novel, quantitative assay for homocarnosine in cerebrospinal fluid using stable-isotope dilution liquid chromatography–tandem mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2006, 830, 196-200.	2.3	27
114	Expression profiling reveals multiple myelin alterations in murine succinate semialdehyde dehydrogenase deficiency. Journal of Inherited Metabolic Disease, 2006, 29, 143-156.	3.6	25
115	Succinic Semialdehyde Dehydrogenase Deficiency: GABAB receptor-mediated function. Brain Research, 2006, 1090, 15-22.	2.2	62
116	Status epilepticus in mice deficient for succinate semialdehyde dehydrogenase: GABAA receptor-mediated mechanisms. Annals of Neurology, 2006, 59, 42-52.	5.3	61
117	Murine succinate semialdehyde dehydrogenase (SSADH) deficiency, a heritable disorder of GABA metabolism with epileptic phenotype. IUBMB Life, 2005, 57, 639-644.	3.4	29
118	Inherited disorders of neurotransmitters in children and adults. Clinical Biochemistry, 2005, 38, 1051-1058.	1.9	80
119	Determination of the GABA analogue succinic semialdehyde in urine and cerebrospinal fluid by dinitrophenylhydrazine derivatization and liquid chromatography–tandem mass spectrometry: Application to SSADH deficiency. Journal of Inherited Metabolic Disease, 2005, 28, 913-920.	3.6	28
120	Gamma-hydroxybutyric aciduria: A biochemist's education from a heritable disorder of GABA metabolism. Journal of Inherited Metabolic Disease, 2005, 28, 247-265.	3.6	14
121	γ-Hydroxybutyric Acid. New England Journal of Medicine, 2005, 352, 2721-2732.	27.0	285
122	Liver-Directed Adenoviral Gene Transfer in Murine Succinate Semialdehyde Dehydrogenase Deficiency. Molecular Therapy, 2004, 9, 527-539.	8.2	25
123	Absence seizures in succinic semialdehyde dehydrogenase deficient mice: a model of juvenile absence epilepsy. Pharmacology Biochemistry and Behavior, 2004, 79, 547-553.	2.9	65
124	Oxidation of 4-hydroxy-2-nonenal by succinic semialdehyde dehydrogenase (ALDH5A). Journal of Neurochemistry, 2004, 86, 298-305.	3.9	63
125	??-Hydroxybutyric Acid. Toxicological Reviews, 2004, 23, 3-20.	2.5	84
126	From the street to the brain: neurobiology of the recreational drug γ-hydroxybutyric acid. Trends in Pharmacological Sciences, 2004, 25, 29-34.	8.7	175

#	Article	IF	CITATIONS
127	Seizure evolution and amino acid imbalances in murine succinate semialdehyde dehydrogenase (SSADH) deficiency. Neurobiology of Disease, 2004, 16, 556-562.	4.4	54
128	Photosensitive absence epilepsy with myoclonias and heterozygosity for succinic semialdehyde dehydrogenase (SSADH) deficiency. Clinical Neurophysiology, 2004, 115, 1417-1422.	1.5	32
129	Clinical aspects of the disorders of GABA metabolism in children. Current Opinion in Neurology, 2004, 17, 107-113.	3.6	64
130	Mutational spectrum of the succinate semialdehyde dehydrogenase (ALDH5A1) gene and functional analysis of 27 novel disease-causing mutations in patients with SSADH deficiency. Human Mutation, 2003, 22, 442-450.	2.5	117
131	Murine succinate semialdehyde dehydrogenase deficiency. Annals of Neurology, 2003, 54, S81-S90.	5.3	48
132	Succinic semialdehyde dehydrogenase deficiency in children and adults. Annals of Neurology, 2003, 54, S73-S80.	5.3	108
133	Magnetic resonance spectroscopy of neurotransmitters in human brain. Annals of Neurology, 2003, 54, S25-S31.	5.3	126
134	Monitoring of 4-hydroxybutyric acid levels in body fluids during vigabatrin treatment in succinic semialdehyde dehydrogenase deficiency. Annals of Neurology, 2003, 54, 686-689.	5.3	39
135	Significant behavioral disturbances in succinic semialdehyde dehydrogenase (SSADH) deficiency (Gamma-Hydroxybutyric aciduria). Biological Psychiatry, 2003, 54, 763-768.	1.3	103
136	Clinical spectrum of succinic semialdehyde dehydrogenase deficiency. Neurology, 2003, 60, 1413-1417.	1.1	191
137	Therapeutic Intervention in Mice Deficient for Succinate Semialdehyde Dehydrogenase (γ-Hydroxybutyric Aciduria). Journal of Pharmacology and Experimental Therapeutics, 2002, 302, 180-187.	2.5	81
138	Structure of human succinic semialdehyde dehydrogenase gene: identification of promoter region and alternatively processed isoforms. Molecular Genetics and Metabolism, 2002, 76, 348-362.	1.1	49
139	Focal neurometabolic alterations in mice deficient for succinate semialdehyde dehydrogenase. Journal of Neurochemistry, 2002, 81, 71-79.	3.9	53
140	Enzymatic and Immunologic Identification of Succinic Semialdehyde Dehydrogenase in Rat and Human Neural and Nonneural Tissues. Journal of Neurochemistry, 2002, 65, 851-855.	3.9	26
141	Pharmacologic rescue of lethal seizures in mice deficient in succinate semialdehyde dehydrogenase. Nature Genetics, 2001, 29, 212-216.	21.4	149
142	Development of a Stable-Isotope Dilution Assay for γ-Aminobutyric Acid (GABA) Transaminase in Isolated Leukocytes and Evidence That GABA and β-Alanine Transaminases Are Identical. Clinical Chemistry, 2001, 47, 525-531.	3.2	20
143	Delayed-onset dystonia associated with 3-oxothiolase deficiency. Movement Disorders, 2001, 16, 372-375.	3.9	22
144	Organization of the mevalonate kinase (MVK) gene and identification of novel mutations causing mevalonic aciduria and hyperimmunoglobulinaemia D and periodic fever syndrome. European Journal of Human Genetics, 2001, 9, 253-259.	2.8	85

#	Article	IF	CITATIONS
145	Development of a stable-isotope dilution assay for gamma-aminobutyric acid (GABA) transaminase in isolated leukocytes and evidence that GABA and beta-alanine transaminases are identical. Clinical Chemistry, 2001, 47, 525-31.	3.2	9
146	Fetal demise with Smith-Lemli-Opitz syndrome confirmed by tissue sterol analysis and the absence of measurable 7-dehydrocholesterol ?7-reductase activity in chorionic villi. , 2000, 20, 238-240.		30
147	Molecular characterization of methylmalonate semialdehyde dehydrogenase deficiency. Journal of Inherited Metabolic Disease, 2000, 23, 497-504.	3.6	48
148	MRI Findings in Succinic Semialdehyde Dehydrogenase Deficiency. Neuropediatrics, 2000, 31, 45-46.	0.6	22
149	Fetal demise with Smith–Lemli–Opitz syndrome confirmed by tissue sterol analysis and the absence of measurable 7â€dehydrocholesterol Δ7â€reductase activity in chorionic villi. Prenatal Diagnosis, 2000, 20, 238-240.	2.3	1
150	2-Methylbutyryl-Coenzyme A Dehydrogenase Deficiency: A New Inborn Error of L-Isoleucine Metabolism. Pediatric Research, 2000, 47, 830-833.	2.3	92
151	Relationship between Kinetic Properties of Mutant Enzyme and Biochemical and Clinical Responsiveness to Biotin in Holocarboxylase Synthetase Deficiency. Pediatric Research, 1999, 46, 671-671.	2.3	35
152	Unusual enzyme findings in five patients with metabolic profiles suggestive of succinic semialdehyde dehydrogenase deficiency (4-hydroxybutyric aciduria). Journal of Inherited Metabolic Disease, 1998, 21, 255-261.	3.6	7
153	Variable clinical presentation in three patients with 3-methylglutaconyl-coenzyme A hydratase deficiency. Journal of Inherited Metabolic Disease, 1998, 21, 631-638.	3.6	19
154	Hematological abnormalities and cholestatic liver disease in two patients with mevalonate kinase deficiency. American Journal of Medical Genetics Part A, 1998, 78, 408-412.	2.4	56
155	3-Methylcrotonyl-coenzyme A carboxylase deficiency in Amish/Mennonite adults identified by detection of increased acylcarnitines in blood spots of their children. Journal of Pediatrics, 1998, 132, 519-523.	1.8	72
156	Two Exon-Skipping Mutations as the Molecular Basis of Succinic Semialdehyde Dehydrogenase Deficiency (4-Hydroxybutyric Aciduria). American Journal of Human Genetics, 1998, 63, 399-408.	6.2	73
157	4-Hydroxybutyric Acid and the Clinical Phenotype of Succinic Semialdehyde Dehydrogenase Deficiency, an Inborn Error of GABA Metabolism. Neuropediatrics, 1998, 29, 14-22.	0.6	128
158	The Clinical Phenotype of Succinic Semialdehyde Dehydrogenase Deficiency (4-Hydroxybutyric) Tj ETQq0 0 0 rgBT	Oyerlock	2 10 Tf 50 22 134
159	Phenotypically mild presentation in a patient with 2-methylacetoacetyl-coenzyme A (β-keto)thiolase deficiency. Journal of Inherited Metabolic Disease, 1997, 20, 712-713.	3.6	9
160	Seizures in a boy with succinic semialdehyde dehydrogenase deficiency treated with vigabatrin (γ-vinyl-GABA). Journal of Inherited Metabolic Disease, 1996, 19, 313-318.	3.6	34
161	Vigabatrin therapy in six patients with succinic semialdehyde dehydrogenase deficiency. Journal of Inherited Metabolic Disease, 1995, 18, 143-146.	3.6	50

162Gamma-aminobutyric acid (GABA) metabolism in mammalian neural and nonneural tissues. Comparative<br/>Biochemistry and Physiology A, Comparative Physiology, 1995, 112, 247-263.0.6163

#	Article	IF	CITATIONS
163	Molecular Cloning of the Mature NAD+-dependent Succinic Semialdehyde Dehydrogenase from Rat and Human. Journal of Biological Chemistry, 1995, 270, 461-467.	3.4	70
164	Fatal cardiomyopathy associated with 3-hydroxy-3-methylglutaryl-CoA lyase deficiency. Journal of Inherited Metabolic Disease, 1994, 17, 291-294.	3.6	37
165	Pre- and postnatal diagnosis of succinic semialdehyde dehydrogenase deficiency using enzyme and metabolite assays. Journal of Inherited Metabolic Disease, 1994, 17, 732-737.	3.6	20
166	3â€METHYLGLUTACONIC ACIDURIA IN THE IRAQIâ€JEWISH "OPTIC ATROPHY PLUSâ€~ (COSTEFF) SYNDROME Developmental Medicine and Child Neurology, 1994, 36, 167-172.	2.1	30
167	Enzymatic and immunological demonstration of normal and defective succinic semialdehyde dehydrogenase activity in fetal brain, liver and kidney. Journal of Inherited Metabolic Disease, 1993, 16, 523-526.	3.6	14
168	Multiple syndromes of 3-methylglutaconic aciduria. Pediatric Neurology, 1993, 9, 120-123.	2.1	66
169	Stable-Isotope Dilution Analysis of D- and L-2-Hydroxyglutaric Acid: Application to the Detection and Prenatal Diagnosis of D- and L-2-Hydroxyglutaric Acidemias. Pediatric Research, 1993, 34, 277-280.	2.3	117
170	3-Methylglutaconic aciduria associated with Pearson syndrome and respiratory chain defects. Journal of Pediatrics, 1992, 121, 940-942.	1.8	50
171	Further evaluation of Vigabatrin therapy in 4-hydroxybutyric aciduria. European Journal of Pediatrics, 1992, 151, 466-466.	2.7	17
172	Succinic semialdehyde dehydrogenase from mammalian brain: Subunit analysis using polyclonal antiserum. International Journal of Biochemistry & Cell Biology, 1992, 24, 1493-1499.	0.5	52
173	Phenotypic heterogeneity in the syndromes of 3-methylglutaconic aciduria. Journal of Pediatrics, 1991, 118, 885-890.	1.8	57
174	4-Hydroxybutyric aciduria: Application of a fluorometric assay to the determination of succinic semialdehyde dehydrogenase activity in extracts of cultured human lymphoblasts. Clinica Chimica Acta, 1991, 196, 219-221.	1.1	52
175	Stable isotope dilution analysis of 4-hydroxybutyric acid: An accurate method for quantification in physiological fluids and the prenatal diagnosis of 4-hydroxybutyric aciduria. Biological Mass Spectrometry, 1990, 19, 89-93.	0.5	89
176	3-Hydroxy-3-methylglutaryl-CoA lyase deficiency as detected by radiochemical assay in cell extracts by thin-layer chromatography, and identification of three new cases. Clinical Chemistry, 1990, 36, 297-303.	3.2	23
177	3-Hydroxy-3-methylglutaryl coenzyme A reductase activity in cultured fibroblasts from patients with mevalonate kinase deficiency: differential response to lipid supplied by fetal bovine serum in tissue culture medium. Journal of Lipid Research, 1990, 31, 515-21.	4.2	50
178	3-Hydroxy-3-methylglutaryl-CoA lyase deficiency as detected by radiochemical assay in cell extracts by thin-layer chromatography, and identification of three new cases. Clinical Chemistry, 1990, 36, 297-303.	3.2	12
179	Mevalonate Kinase in Lysates of Cultured Human Fibroblasts and Lymphoblasts: Kinetic Properties, Assay Conditions, Carrier Detection and Measurement of Residual Activity in a Patient with Mevalonic Aciduria. Enzyme, 1989, 41, 47-55.	0.7	27
180	Metabolism of [U-14C]-4-hydroxybutyric acid to intermediates of the tricarboxylic acid cycle in extracts of rat liver and kidney mitochondria. European Journal of Drug Metabolism and Pharmacokinetics, 1989, 14, 61-70.	1.6	15

#	Article	IF	CITATIONS
181	VIGABATRIN THERAPY IN PATIENT WITH SUCCINIC SEMIALDEHYDE DEHYDROGENASE DEFICIENCY. Lancet, The, 1989, 334, 1105-1106.	13.7	32
182	Succinic semialdehyde dehydrogenase deficiency associated with combined 4-hydroxybutyric and dicarboxylic acidurias: Potential for clinical misdiagnosis based on urinary organic acid profiling. Journal of Pediatrics, 1989, 114, 607-610.	1.8	23
183	3-hydroxy-3-methylglutaryl-coenzyme a lyase deficiency: Report of five new patients. Journal of Inherited Metabolic Disease, 1988, 11, 76-87.	3.6	48
184	3-hydroxy-3-methylglutaryl-coenzyme A lyase deficiency: review of 18 reported patients. European Journal of Pediatrics, 1988, 148, 180-186.	2.7	115
185	4-Hydroxybutyric aciduria in a patient without ataxia or convulsions. European Journal of Pediatrics, 1988, 147, 529-531.	2.7	15
186	Oxidation of [U-14C]Succinic Semialdehyde in Cultured Human Lymphoblasts: Measurement of Residual Succinic Semialdehyde Dehydrogenase Activity in 11 Patients with 4-Hydroxybutyric Aciduria. Pediatric Research, 1988, 24, 455-460.	2.3	36
187	Mevalonic aciduria: Family studies in mevalonate kinase deficiency, an inborn error of cholesterol biosynthesis. Journal of Inherited Metabolic Disease, 1987, 10, 282-285.	3.6	14
188	Succinic semialdehyde dehydrogenase deficiency: an inborn error of gamma-aminobutyric acid metabolism. Clinica Chimica Acta, 1983, 133, 33-42.	1.1	73